BioSpace News Archive

Drug Development

Regeneron’s High-Dose Eylea Allows for Longer Dosing Intervals in wAMD

Ahead of an FDA decision in the third quarter, Regeneron is touting promising durability data from the Phase III PULSAR trial for higher-dose Eylea in patients with wet age-related macular degeneration.

August 11, 2023
·
2 min read
·
Tristan Manalac
Employer Resources

Addressing the UK’s Scientific Skills Gap

If we want to make the UK a scientific superpower, we need to address the elephant in the room: the skills gap.

August 11, 2023
·
5 min read
·
James Sheppard, UK MD at Kadans
Drug Development

ALX Oncology Axes Two CD47 Programs on Disappointing Results

The clinical-stage company joins several others in the anti-CD47 space which have dropped studies amid poor results, including Gilead Sciences’ decision late last month to stop a Phase III trial.

August 11, 2023
·
2 min read
·
Connor Lynch
Deals

SEC Investigating Illumina’s Multi-Billion Dollar Merger with GRAIL

The Securities and Exchange Commission has joined the mounting antitrust scrutiny of Illumina’s acquisition of the cancer diagnostics company, according to an SEC filing by the DNA sequencing giant.

August 11, 2023
·
2 min read
·
Tristan Manalac
Drug Development

CRISPR Shows Preclinical Promise in Treating Alzheimer’s, Challenges Persist

At AAIC, researchers presented studies using CRISPR-Cas9 in animal/organoid models of Alzheimer’s disease, but some experts doubt that such approaches will successfully translate to humans.

August 11, 2023
·
6 min read
·
Heather McKenzie
Policy

SCOTUS Blocks $6B Purdue Pharma Bankruptcy Settlement

The Supreme Court of the United States has granted the Department of Justice’s motion for a stay regarding Purdue’s bankruptcy case and is set to assess the legality of the settlement in December.

August 11, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Launch of Insilico’s Phase II Program Highlights Generative AI Momentum

Insilico’s AI platform has attracted interest from a growing number of biopharma companies. Meanwhile, several other firms highlight their own AI technologies.

August 11, 2023
·
5 min read
·
Ana Mulero
Syner-G Biopharma Group Announces Karen Casey as Chief People Officer

January 10, 2023, Boston, MA — Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to the pharmaceutical and medical device industries, today announced that Karen Casey has joined the organization as the chief people officer.

August 11, 2023
·
1 min read
Policy

Ultragenyx Sued by Henrietta Lacks’ Family in Second HeLa Cell Line Lawsuit

After reaching a settlement with Thermo Fisher earlier this month, the family of Henrietta Lacks is now suing Ultragenyx for its “unjust enrichment” using their matriarch’s immortal cell line.

August 11, 2023
·
2 min read
·
Kate Goodwin
Business

Week in Review: Novo Nordisk Riding High, Novavax in the Black (For Now), Nektar Sues Lilly and More

Novo’s weight-loss drug Wegovy improves cardiovascular outcomes, Novavax posts surprise Q2 profit, while Nektar Therapeutics files lawsuit against Eli Lilly for misconduct in drug development deal.

August 11, 2023
·
2 min read
·
Greg Slabodkin